Mylan N.V.’s $1 Billion Senior Debt Offering
December 09, 2015
Cravath represented Mylan N.V. in connection with its US$1 billion Rule 144A/Reg. S investment grade senior debt offering. Mylan N.V. is a leading global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The notes will be listed on the Irish Stock Exchange. The transaction closed on December 9, 2015.
The Cravath team included partner William V. Fogg and associates Benjamin S. Persina and Douglas C. Dolan on securities matters and partner J. Leonard Teti II and associate Kiran Sheffrin on tax matters. Jin‑Kyu Baek also worked on securities matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1991, Columbia Law SchoolHarlan Fiske Stone Scholar
-
A.B., 1988, Brown Universitymagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2005, University of Virginia School of LawOrder of the Coif
-
A.B., 1999, Princeton Universitywith Honors
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
April 29, 2024
Mylan’s Appellate Win Affirming Summary Judgment in Securities Class Action
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
